Eli Lilly and Co.’s oral selective estrogen receptor degrader (SERD) imlunestrant has been approved by the U.S. FDA for ...

Coronary artery bypass graft (CABG) surgery remains the gold standard treatment for patients with severe atherosclerosis, but ...

Youthbio Therapeutics Inc. has held a successful INTERACT meeting with the FDA for its lead Alzheimer’s candidate, YB-002.

Boehringer Ingelheim Pharma GmbH & Co KG has advanced a novel T-cell engager resulting from a collaboration with Numab ...

The U.S. FDA released a trio of draft guidances to help sponsors in developing and monitoring cell and gene therapies, as ...

The threat of tariffs on imports of branded drugs is about to be realized after U.S. President Donald Trump announced a 100% ...

Rakuten Medical Inc. is advancing a pipeline of solid tumor therapeutics built on its Alluminox platform worldwide, having ...

Is there a link between cellular senescence and multiple sclerosis (MS) progression? Several presentations at this year’s ...

Xeltis BV reported successful clinical data from the Axess EU pivotal trial which demonstrated the transformative potential of its restorative vascular access conduit, Axess, in hemodialysis treatment ...

As President Donald Trump promised again in a Sept. 23 media briefing, most-favored-nation (MFN) prescription drug pricing could soon come to America.

Renal cell carcinoma accounts for approximately 90% of kidney cancers, and current treatments fail to prevent metastasis in up to 40% of patients. Potentially effective is immunotherapy based on CAR T ...

A month after raising $55 million to advance its AI-enhanced ultrasound diagnostics for cardiovascular disease, Ultromics Ltd. presented strong results for its U.S. FDA-cleared AI analysis of ...